All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On the 1st February 2018, Antony R Mato, from the Division of Hematology and Oncology at the University of Pennsylvania, Philadelphia, PA and colleagues, had an article published online ahead of print in Haematologica which reported a real-world retrospective analysis of the safety of ibrutinib in chronic lymphocytic leukemia (CLL) patients treated at nine US cancer centers registered in the ConnectTM CLL Registry.
Clinically approved ibrutinib—a Bruton’s tyrosine kinase (BTK) inhibitor—has demonstrated differential side effects to traditional chemotherapy, which have restricted its clinical use, following accumulating evidence from phase III trials, like RESONATE, RESONATE 2 and HELIOS. The aim of this multicenter, retrospective study was to compare the type and frequency of reported ibrutinib-mediated toxicities in CLL patients. The primary endpoint of this study was progression-free survival (PFS) and secondary endpoints included overall survival (OS) and reasons for discontinuation.
The results of this study provided a detailed account on the main reasons for ibrutinib discontinuation in both clinical trial and community treatment settings and established a discontinuation timeline for all toxicity types reported. According to the authors, the main limitation of this study is its retrospective and multicentric nature, that might affect data consistency. Nevertheless, this work provides a valuable tool for the development of future management strategies to alleviate ibrutinib intolerance and to maximize its treatment efficacy for CLL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox